









Markets
/
Stocks
/
nasdaq-ifrx
/

InflaRx NV

IFRX

1.270USD

-0.110-7.97%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

86.04MMarket Cap

LossP/E TTM



InflaRx NV

1.270

-0.110-7.97%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of InflaRx NV

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

InflaRx NV's Score

Industry at a Glance

Industry Ranking

151 / 407

Overall Ranking

282 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

4.143

Target Price

+183.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

InflaRx NV Highlights

StrengthsRisks

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Growing

The company is in a growing phase, with the latest annual income totaling USD 152.79K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 152.79K.

Fairly Valued

The company’s latest PE is -2.23, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.71M shares, decreasing 24.47% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.71.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.65, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 33.80K, representing a year-over-year increase of 480.57%, while its net profit experienced a year-over-year increase of 2.55%.

Score

Industry at a Glance

Previous score

5.65

Change



Financials

5.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.11

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

InflaRx NV's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.64, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -2.23, which is -52.69% below the recent high of -1.05 and -396.08% above the recent low of -11.06.

Score

Industry at a Glance

Previous score

6.64

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 151/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for InflaRx NV is 3.00, with a high of 10.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

4.143

Target Price

+200.21%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

InflaRx NV

IFRX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.94, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.68 and the support level at 1.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.23

Change

-0.29

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.012

Neutral

RSI(14)

46.598

Neutral

STOCH(KDJ)(9,3,3)

27.080

Sell

ATR(14)

0.167

High Vlolatility

CCI(14)

-48.048

Neutral

Williams %R

77.193

Sell

TRIX(12,20)

0.161

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.362

Sell

MA10

1.387

Sell

MA20

1.354

Sell

MA50

1.373

Sell

MA100

1.110

Buy

MA200

1.311

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 24.67%, representing a quarter-over-quarter decrease of 34.14%. The largest institutional shareholder is Steven Cohen, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Suvretta Capital Management, LLC

6.48M

683 Capital Management LLC

2.48M

-5.71%

RA Capital Management, LP

1.97M

Guo (Renfeng M.D.)

1.76M

Eversept Partners, LP

1.64M

-2.12%

Riedemann (Niels C. M.D.)

1.07M

Mark (Christian Kubler)

960.01K

Woodline Partners LP

751.27K

+0.04%

Ikarian Capital LLC

705.01K

Morgan Stanley & Co. LLC

693.35K

-45.02%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 1.92, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.